Inositol and human reproduction. From cellular metabolism to clinical use

References

• Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002;3:47–60
   PubMedGoogle Scholar
• Ju S, Shaltiel G, Shamir A, et al. Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J Biol Chem 2004;279:21759–65
   PubMed Web of Science ®Google Scholar
• Clements RS, Jr Darnell B. Myo-inositol content of common foods: development of a high myo-inositol diet. Am J Clin Nutr 1980;33:1954–67
   PubMed Web of Science ®Google Scholar
• Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006;443:651–7
   PubMed Web of Science ®Google Scholar
• Larner J, Brautigan DL, Thorner MO. DChiroInositol glycans in insulin signaling and insulin resistance. Mol Med 2010;16:543–52
   PubMed Web of Science ®Google Scholar
• Unfer V, Raffone E, Rizzo P, et al. Effect of a supplementation with myoinositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol 2011;27:857–61
   PubMed Web of Science ®Google Scholar
• Sun TH, Heimark DB, Nguygen T, et al. Both myoinositol to chiroinositol epimerase activities and chiroinositol to myoinositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002;293:1092–8
   PubMed Web of Science ®Google Scholar
• Isabella R, Raffone E. Does ovary need D-chiro-inositol? J Ovarian Res 2012;5:14
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon JP, et al. Contribution of myoinositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009;147:120–3
   PubMed Web of Science ®Google Scholar
• Larner JD, Huang LC. Identification of a novel inositol glycan signaling pathway with significant therapeutic relevance to insulin resistance: an insulin signaling model using both tyrosine kinase and G proteins. Diabetes Rev 1999;7:217–31
   Google Scholar
• Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol 2011;27:256–62
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myoinositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28:509–15
   PubMed Web of Science ®Google Scholar
• Chiu TT, Rogers MS, Law EL, et al. Follicular fluid and serum concentrations of myoinositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591–6
   PubMed Web of Science ®Google Scholar
• Brusco GF1, Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci 2013;17:3095–102
   PubMed Web of Science ®Google Scholar
• D'Anna R, Di Benedetto V, Rizzo P, et al. Myoinositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012;28:440–2
   PubMed Web of Science ®Google Scholar
• Gloaguen P, Crépieux P, Heitzler D, et al. Mapping the follicle stimulating hormone induced signaling networks. Front Endocrinol (Lausanne) 2011;2:45
   PubMedGoogle Scholar
• Breen SM, Andric N, Ping T, et al. Ovulation involves the luteinizing hormone-dependent activation of G(q/11) in granulosa cells. Mol Endocrinol 2013;27:1483–91
   PubMed Web of Science ®Google Scholar
• Allen MD, Neumann S, Gershengorn MC. Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling. FASEB J 2011;25:3687–94
   PubMed Web of Science ®Google Scholar
• Zhu X, Gilbert S, Birnbaumer M, et al. Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density. Mol Pharmacol 1994;46:460–9
   PubMed Web of Science ®Google Scholar
• Tosti E. Calcium ion currents mediating oocyte maturation events. Reprod Biol Endocrinol 2006;4:26
   PubMed Web of Science ®Google Scholar
• Chiu TT1, Rogers MS, BritonJones C, et al. Effects of myoinositol on the invitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003;18:408–16
   PubMed Web of Science ®Google Scholar
• Larner J. Multiple pathways in insulin signallingfitting the covalent and allosteric puzzle pieces together. Endocr J 1994;2:167–71
   Google Scholar
• Bogan JS. Regulation of glucose transporter translocation in health and diabetes. Annu Rev Biochem 2012;81:507–32
   PubMed Web of Science ®Google Scholar
• Roach PJ. Control of glycogen synthase by hierarchal protein phosphorylation. FASEB J 1990;4:2961–8
   PubMed Web of Science ®Google Scholar
• Sleight S, Wilson B, Heimark D, et al. G(q/11) is involved in insulin stimulated inositol phosphoglycan putative mediator generation in rat liver membranes: colocalization of G(q/11) with the insulin receptor in membrane vesicles. Biochem Biophys Res Commun 2002;295:561–9
   PubMed Web of Science ®Google Scholar
• Larner J, Price JD, Heimark D, et al. Isolation, structure, synthesis, and bioactivity of a novel putative insulin mediator. A galactosamine chiroinositol pseudodisaccharide Mn2+ chelate with insulinlike activity. J Med Chem 2003;46:3283–91
   PubMed Web of Science ®Google Scholar
• Dang NT, Mukai R, Yoshida K, et al. D-pinitol and myoinositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci Biotechnol Biochem 2010;74:1062–7
   PubMed Web of Science ®Google Scholar
• Brautigan DL, et al. Allosteric activation of protein phosphatase 2C by D-chiro-inositol-galactosamine, a putative mediator mimetic of insulin action. Biochemistry 2005;44:11067–73
   PubMed Web of Science ®Google Scholar
• Jarett L, Seals JR. Pyruvate dehydrogenase activation in adipocyte mitochondria by an insulin-generated mediator from muscle. Science 1979;206:1407–8
   PubMed Web of Science ®Google Scholar
• Wallace TM, Matthews DR. The assessment of insulin resistance man. Diabetic Med 2002;19:527–34
   PubMed Web of Science ®Google Scholar
• Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–93
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular dis ease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AEPCOS) society. J Clin Endocrinol Metab 2010;95:2038–49
   PubMed Web of Science ®Google Scholar
• Kennington AS, Hill CR, Craig J, et al. Low urinary chiroinositol excretion in noninsulindependent diabetes mellitus. N Engl J Med 1990;323:373–8
   PubMed Web of Science ®Google Scholar
• Ostlund RE, McGill JB, Herskowitz I, et al. Dchiroinositol metabolism in diabetes mellitus. Proc Natl Acad Sci U S A 1993;90:9988–92
   PubMed Web of Science ®Google Scholar
• Larner J, Craig J. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care 1996;19:76–8
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Diamanti-Kandarakis E, Ostlund RE, Jr et al. Altered Dchiroinositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–5
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndromeGynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiroinositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 2014;30:438–43
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRMSponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013;6:1–13
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Falcon de Vargas A, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001–5
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–9
   PubMed Web of Science ®Google Scholar
• Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002;102:151–66
   PubMed Web of Science ®Google Scholar
• Zhang LH, Rodriguez H, Ohno S, et al. Serine phosphorylation of human P450c17 increases 17,20lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995;92:10619–23
   PubMed Web of Science ®Google Scholar
• Patel K, Coefler MS, Dahan MH, et al. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab 2003;88:5456–61
   PubMed Web of Science ®Google Scholar
• Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebocontrolled trial: effects of myoinositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347–54
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Prati A, Santagni S, et al. Differential insulin response to myoinositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012;28:969–73
   PubMed Web of Science ®Google Scholar
• Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508–13
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of dchiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar
• Colazingari S, Fiorenza MT, Carlomagno G, et al. Improvement of mouse embryo quality by myoinositol supplementation of IVF media. J Assist Reprod Genet 2014;31:463–9
   PubMed Web of Science ®Google Scholar
• Higgins BD1, Kane MT. Inositol transport in mouse oocytes and preimplantation embryos: effects of mouse strain, embryo stage, sodium and the hexose transport inhibitor, phloridzin. Reproduction 2003;125:111–18
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to d-chiro-inositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 2014;21:854–8
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V Baillargeon JP, et al. Myoinositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750–4
   PubMed Web of Science ®Google Scholar
• Caprio F, D'Eufemia MD, Trotta C, et al. Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. J Ovarian Res 2015;8:37
   PubMed Web of Science ®Google Scholar
• Cheang KI, Baillargeon JP, Essah PA, et al. Insulin stimulated release of D-Chiro-Inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metab Clin Exp 2008;57:1390–7
   PubMed Web of Science ®Google Scholar
• Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;95:2515–16
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Jakubowicz DJ, et al. Metformin therapy increases insulinstimulted release of Dchiroinositolcontaining inositolophosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242–9
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Di Cello A, et al. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertil Steril 2011;96:1128–33
   PubMed Web of Science ®Google Scholar
• Heimark D, McAllister J, Larner J. Decreased myoinositol to chiroinositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 2014;61:111–17
   PubMed Web of Science ®Google Scholar
• Unfer V, Porcaro G. Updates on the myoinositol plus Dchiroinositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol 2014;7:623–31
   PubMed Web of Science ®Google Scholar
• Colazingari S, Treglia M, Najjar R, et al. The combined therapy myoinositol plus Dchiroinositol, rather than Dchiroinositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 2013;288:1405–11
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Carlomagno G, Gerli S, et al. Results from the International Consensus Conference on myoinositol and Dchiroinositol in Obstetrics and Gynecology assisted reproduction technology. Gynecol Endocrinol 2015;31:441–6
   PubMed Web of Science ®Google Scholar
• Nestler JE. Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions. J Basic Clin Physiol Pharmacol 1998;9:197–204
   PubMedGoogle Scholar
• La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2015;31:52–6
   PubMed Web of Science ®Google Scholar
• Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myoinositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 2013;29:375–9
   PubMed Web of Science ®Google Scholar